A Single Streptomyces Symbiont Makes Multiple Antifungals to Support the Fungus Farming Ant Acromyrmex octospinosus

Ryan F. Seipke ; Joerg Barke ; Charles Brearley ; Lionel Hill ; Douglas W. Yu ; Rebecca J. M. Goss ; Matthew I. Hutchings PLos ONE 2011, 6 (8) e22028 Attine ants are dependent on a cultivated fungus for food and use antibiotics produced by symbiotic Actinobacteria as weedkillers in their fungus gardens. Actinobacterial species belonging … Read more

Engineering Biofilms for Biocatalysis

Andreas N. Tsoligkas ; Michael Winn ; James Bowen ; Tim W. Overton ; Mark J. H. Simmons ; Rebecca J. M. Goss ChemBioChem 2011, 12 (9) 1391-1395 Biofilm, friend not foe: Single species biofilms can be engineered to form robust biocatalysts with greater catalytic activity and significantly improved catalytic longevity than purified and immobilised enzymes. We … Read more

Diversity in natural product families is governed by more than enzyme promiscuity alone : establishing control of the pacidamycin portfolio

Sabine Grüschow ; Emma J. Rackham ; Rebecca J. M. Goss Chem Sci 2011, 2 2182-2186 As with many other antibiotics, pacidamycins are produced as a suite of related compounds. Unlike most other secondary metabolites, however, this diversity is not solely the result of the substrate promiscuity of the biosynthetic enzymes but also arises from a gene duplication event (Pac21, … Read more

The saponins – polar isoprenoids with important and diverse biological activities

Anne Osbourn ; Rebecca J. M. Goss ; Robert A. Field Nat Prod Rep 2011, 28 1261-1268 Saponins are polar molecules that consist of a triterpene or steroid aglycone with one or more sugar chains. They are one of the most numerous and diverse groups of plant natural products. These molecules have important ecological and agronomic functions, contributing to … Read more

Gene Expression Enabling Synthetic Diversification of Natural Products : Chemogenetic Generation of Pacidamycin Analogs

Abhijeet Deb Roy ; Sabine Grueschow ; Nickiwe Cairns ; Rebecca J. M. Goss JACS 2010, 132 (35) 12243-12245 Introduction of prnA, the halogenase gene from pyrrolnitrin biosynthesis, into Streptomyces coeruleorubidus resulted in efficient in situ chlorination of the uridyl peptide antibotic pacidamycin. The installed chlorine provided a selectably functionalizable handle enabling synthetic modification of the natural product using mild cross-coupling … Read more

A mixed community of actinomycetes produce multiple antibiotics for the fungus farming ant Acromyrmex octospinosus

Joerg Barke ; Ryan F. Seipke ; Sabine Grueschow ; Darren Heavens ; Nizar Drou ; Mervyn J. Bibb ; Rebecca J. M. Goss ; Douglas W. Yu ; Matthew I. Hutchings BMC Biology 2010, 8 109 ttine ants live in an intensely studied tripartite mutualism with the fungus Leucoagaricus gongylophorus, which provides food to the ants, and … Read more

Pacidamycin Biosynthesis : Identification and Heterologous Expression of the First Uridyl Peptide Antibiotic Gene Cluster

Emma J. Rackham ; Sabine Grüschow ; Amany E. Ragab ; Shilo Dickens ; Rebecca J. M. Goss ChemBioChem 2010, 11 (12) 1700-1709 The pacidamycins are antimicrobial nucleoside antibiotics produced by Streptomyces coeruleorubidus that inhibit translocase I, an essential bacterial enzyme yet to be clinically targeted. The novel pacidamycin scaffold is composed of a pseudopeptide backbone linked by … Read more

An Expeditious Route to Fluorinated Rapamycin Analogues by Utilising Mutasynthesis

Rebecca J. M. Goss ; Simon Lanceron ; Abhijeet Deb Roy ; Simon Sprague ; Mohammed Nur-e-Alam ; David L. Hughes ; Barrie Wilkinson ; Steven J. Moss ChemBioChem 2010, 11 (5) 698-702 Rapamycin is a drug with several important clinical uses. Its complex structure means that total synthesis of this natural product and its analogues … Read more

Antimicrobial nucleoside antibiotics targeting cell wall assembly: Recent advances in structure-function studies and nucleoside biosynthesis

Michael Winn ; Rebecca J. M. Goss ; Ken-ichi Kimura ; Timothy D. H. Bugg Nat Prod Rep 2010, 27 279-304 The quest for new antibiotics, especially those with activity against Gram-negative bacteria, is urgent; however, very few new antibiotics have been marketed in the last 40 years, with this limited number falling into only four new structural classes. … Read more